Sunitinib malate is a multitargeted tyrosine kinase inhibitor approved for the treatment of advanced renal-cell carcinoma. We report on an asymptomatic increase in the mean corpuscular volume of ...
Utilization of partial nephrectomy at a cancer center in the modern era. Background: Sunitinib, a multitargeted receptor tyrosine kinase inhibitor represents a standard firstline therapy for advanced ...
Expression of p53, p63 and p73 family of genes in osteosarcoma: Single instituition study of 35 patients using tissue microarray No significant financial relationships to disclose. This is an ASCO ...
When the effectiveness of liver feeding in pernicious anemia was demonstrated by Minot and Murphy in 1926 it was soon noted that, like the macrocytic anemia, the often-present sore tongue, "heartburn" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results